Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan
2012-12-03 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 3 December 2012 - Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare. Further information Media: Mike Rulis +45 4442 3573 [email protected] Ambre Morley (US) +1 609 216 5240 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 78 / 2012
The release as fetched from its publisher. novonordisk.com ↗